Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid

Sponsor
Peking University First Hospital
Study ID
NCT05649579
Status
Completed

Conditions

  • Bullous Pemphigoid

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dupilumab — DRUG
    Duplimab was administered according to the guidelines of the atopic dermatitis treatment regimen, which involved the first dose of 600 mg followed by 300 mg every two weeks. Because of comorbidities or the side effects of corticosteroid, some patients used dupilumab in the initial course of treatment, while others added dupilumab when the traditional drugs proved ineffective. The discontinuation was a joint decision between treating dermatologists and patients. Concomitant medicine was decided by clinicians, depending on the assessing of disease status and patients' choices, and reduced according to international guidelines.

Study Details

This study was designed to be a retrospective, multicentre, observational study to evaluate the efficacy and safety of dupilumab in the treatment of bullous pemphigoid and to find predictors of efficacy.

Key Dates

Start date
Sep 1, 2022
Status verified
Dec 2023
Primary completion
Dec 31, 2022
Completion
Jan 31, 2023

Study Design

Enrollment
146 participants (actual)

Primary Outcome Measure

Proportion of patients reached disease control [ Time Frame: within 4 weeks ]

Related Studies